RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.8934
+0.0234 (2.69%)
At close: Aug 21, 2025, 4:00 PM
0.9099
+0.0165 (1.85%)
After-hours: Aug 21, 2025, 6:47 PM EDT
RenovoRx Revenue
RenovoRx had revenue of $422.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $662.00K. In the year 2024, RenovoRx had annual revenue of $43.00K.
Revenue (ttm)
$662.00K
Revenue Growth
n/a
P/S Ratio
38.80
Revenue / Employee
$66,200
Employees
10
Market Cap
32.74M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RNXT News
- 1 day ago - RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025 - Business Wire
- 7 days ago - RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review - Business Wire
- 15 days ago - RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire - GlobeNewsWire
- 24 days ago - RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - Business Wire
- 5 weeks ago - RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET - Business Wire
- 3 months ago - RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - Business Wire